Following a report by CNBC alleging Apple (AAPL) is in late stages of developing an optical continuous blood glucose sensor, Stephens analyst Chris Cooley reiterates an Overweight rating and $95 price target on Dexom's (DXCM) shares. While the news will likely cause concern, the analyst says investors must recall any potential entrant will have to match Dexom's industry leading clinical efficacy. Given that he is not aware of any formal clinical trials underway by Apple, a pre-requisite for domestic commercialization, Cooley believes this potential threat appears more distant in nature.

Welcome to "Fly Insider," The Fly's weekly recap of notable insider stock transactionsNOTABLE INSIDER PURCHASES: Significant insider purchases reported in the prior week from April 15 through April 19 include:Chairman of Ashford (AINC) Montgomery Bennett purchased 200,000 shares of company stock at $4. 91 per share... To see the rest of the story go to thefly.com. See Story Here

Apple quietly acquired Paris-based AI startup Datakalab on December 17, Challenges' David Pargamin reports. The terms of the transaction could not be learned, but European Commission has been notified of the deal, the author notes. Reference Link

Friday's total option volume of 56.7 million contracts resulted in net open interest growth of 6.01 million calls and 5.28 million puts. NVIDIA (NVDA), Tesla (TSLA), Apple (AAPL) and Advanced Micro Devices (AMD) saw the greatest growth. Top five new positions opened include 50k Lyft (LYFT) May-24 20 calls, 44k Energy Transfer (ET) 4/26 weekly 16.5 calls, 43k Las Vegas Sands (LVS) Sep-24 41 calls, 23k Tesla (TSLA) 4/26 weekly 162.5 calls and 21k Papa John's (PZZA) Jun-24 57.5 puts.